Population-level impact of semaglutide 2.4&#x2009;mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial

Cardiovascular Risk and Diseases

Bempedoic Acid Reduces the Risk of Major Adverse Cardiovascular Events Across Patient Subgroups

COMMENTED

Heart Failure

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Lancet Diabetes Endocrinol

Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN, STEP-HFpEF Trials Committees and Investigators

doi: 10.1016/S2213-8587(24)00304-8

Heart Failure

Risk of Heart Failure in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Study

J Rheumatol

Koppikar S, Kuriya B, Udell JA, Yu B, Chu A, Lee DS, Widdifield J, Eder L

doi: 10.3899/jrheum.2024-0866

Cardiovascular Risk and Diseases

Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Eur Heart J

Wilkinson C, Bhatty A, Batra G, Aktaa S, Smith AB, Dwight J, Ruciński M, Chappell S, Alfredsson J, Erlinge D, Ferreira J, Guðmundsdóttir IJ, Hrafnkelsdóttir ÞJ, Ingimarsdóttir IJ, Irs A, Jánosi A, Járai Z, Oliveira-Santos M, Popescu BA, Vasko P, Vinereanu D, Yap J, Bugiardini R, Cenko E, Nadarajah R, Sydes MR, James S, Maggioni AP, Wallentin L, Casadei B, Gale CP, Global Cardiovascular Outcomes Consortium and in collaboration with ACNAP, ACVC, EACVI, EAPC, EAPCI, EHRA, ESC Committee for Young CV Professionals, ESC Registry Committee, HFA, ESC Patient Forum and these Working Groups: aorta and peripheral vascular diseases, atherosclerosis and vascular biology, cardiac cellular electrophysiology, cardiovascular pharmacotherapy, cardiovascular regenerative and restorative medicine, cardiovascular surgery, cellular biology of the heart, e-cardiology, myocardial function, pulmonary circulation and right ventricular function and thrombosis

doi: 10.1093/eurheartj/ehae724

Cardiovascular Risk and Diseases

Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study

BMJ

Conrad N, Molenberghs G, Verbeke G, Zaccardi F, Lawson C, Friday JM, Su H, Jhund PS, Sattar N, Rahimi K, Cleland JG, Khunti K, Budts W, McMurray JJV

doi: 10.1136/bmj-2023-078523

Atrial Fibrillation

Detrimental Impact of Atrial Fibrillation among Patients Hospitalized for Acute Exacerbation of COPD: Results of a Population-Based Study in Spain from 2016 to 2021

J Clin Med

de-Miguel-Diez J, Lopez-de-Andres A, Zamorano-Leon JJ, Hernández-Barrera V, Cuadrado-Corrales N, Jimenez-Sierra A, Jimenez-Garcia R, Carabantes-Alarcon D

doi: 10.3390/jcm13102803

Heart Failure

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

N Engl J Med

Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Møller DV, Treppendahl MB, Verma S, Jensen TJ, Liisberg K, Lindegaard ML, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovský V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Shah SJ, STEP-HFpEF DM Trial Committees and Investigators

doi: 10.1056/NEJMoa2313917

RECOMMENDED

Cardiovascular Risk and DiseasesFurther Publications

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

JAMA Cardiol

Klug EQ, Llerena S, Burgess LJ, Fourie N, Scott R, Vest J, Caldwell K, Kallend D, Stein EA, LIBERATE-HR Investigators

doi: 10.1001/jamacardio.2024.1659

Further Publications

Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial

JAMA Cardiol

Benziger CP, Stebbins A, Wruck LM, Effron MB, Marquis-Gravel G, Farrehi PM, Girotra S, Gupta K, Kripalani S, Munoz D, Polonsky TS, Sharlow A, Whittle J, Harrington RA, Rothman RL, Hernandez AF, Jones WS

doi: 10.1001/jamacardio.2024.1712

Related content

Bempedoic Acid Reduces the Risk of Major Adverse Cardiovascular Events Across Patient Subgroups

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

Risk of Heart Failure in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Study

Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study

Detrimental Impact of Atrial Fibrillation among Patients Hospitalized for Acute Exacerbation of COPD: Results of a Population-Based Study in Spain from 2016 to 2021

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial

Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial